Portfolio

Tags:
  • Alung Technologies, Inc.

    Alung Technologies, Inc.

    ALung Technologies, Inc. is a privately-held Pittsburgh-based developer and manufacturer of innovative lung assist devices. Founded in 1997 as a spin-out of the University of Pittsburgh, ALung has developed the Hemolung RAS as a dialysis-like alternative or supplement to mechanical ventilation. ALung is backed by individual investors and venture firms including Allos Ventures, Birchmere Ventures and West Capital Advisors, LLC.

  • Carmell Therapeutics

    Carmell Therapeutics

    Carmell is a spin out of Carnegie Mellon University that has developed an exciting new concept in biologics: biologically-active materials manufactured from human blood plasma. These plasma-based materials contain a concentration of natural regenerative factors that promote healing, reduce complications, and save healthcare costs. The first product is a putty to treat traumatic bone injuries, reducing infections while accelerating healing of not only the fracture site but also surrounding soft tissues. The fracture augmentation market is a multi-B market where there is no product routinely used. Unlike competing approaches, Carmell's plasma-based products are safe, consistent and inexpensive to produce – truly unique for the industry.

  • Cognition Therapeutics

    Cognition Therapeutics

    Cognition Therapeutics Inc. is a drug discovery and development company located in Pittsburgh, Pennsylvania. Cognition Therapeutics Inc. is focused on the discovery and development of small molecule therapeutics targeting the toxic proteins that cause the cognitive decline associated with Alzheimer's disease and other neuro- degenerative diseases of the human brain.

  • Medrobotics

    Medrobotics

    Medrobotics Corporation is a privately-held, surgical products company with a core competency in robotics. The Company’s vision is to provide more patients with access to minimally invasive surgery. Headquartered in Raynham, Massachusetts, Medrobotics manufactures and markets its flagship product, the Flex® Robotic System, a robot-assisted platform that provides surgeons with single-site access visualization of hard-to-reach anatomical locations.

  • Moonstone Nutrition

    Moonstone Nutrition

    Moonstone Nutrition is a C-Corporation to commercialize a nutraceutical product for preventing kidney stones that was developed by three renown urologists and nephrologists, launching its first product by the end of 2019.  The Company secured an exclusive, world-wide license for the technology that was collaboratively developed at New York University, Harvard and University of California San Francisco.  The company is expanding its product inventory related to the general kidney health space.

  • Rinovum

    Rinovum

    Rinovum® / Ovala®, Inc as the subsidiary, addresses a large and growing market of Incontinence by improving quality of life and having a positive impact on the environment.  Stress Urinary Incontinence (“SUI”) or Light Bladder Leaks (“LBL”) is very common and often not treated today.  It is simply the unintentional leakage of urine when a woman performs an activity such as coughing, sneezing, dancing, running, etc... Ovala’s product Revive® is first in class and an FDA authorized to market device that takes an Rx device directly to the consumer, OTC.  Revive is in the US Market today, in a new category of women’s health.

  • Wellbridge Health

    Wellbridge Health

    Wellbridge has developed a personalized combination of mobile technology, tele-health monitoring, assessment protocols, and social work-based interventions to uncover and address social barriers to care, and avoid unnecessary emergency room (ER) visits and hospitalizations. Via the BridgIT™ tele-health platform, Wellbridge monitors high-risk, high-cost Medicaid and Medicare Dual-Eligible beneficiaries in their home setting on a daily basis. This evidence-based protocol-driven tele-health solution optimizes human interaction and technology to achieve long-term behavior change and better health outcomes for the patients.